Explain this page
Arphra AIPlain-English read on Incyte Corporation’s valuationInsider signal · 90d
Net sellers
Bought
$0
Sold
$3.6M
Txns
2
Over the trailing 90 days insiders are net sellers — $0 bought against $3.6M sold across 2 open-market Form-4 transactions. Much insider selling is scheduled (10b5-1); read the asymmetry, not any single print.
Open-market Form 4
· insider_tradesInsider transactions · last 180d
Net −$14.8M0 buys
| Insider | Role | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| CAGNONI PABLO J | officer: President, Global Head of R&D | Sell | −18,667 | $1.8M | Apr 17, 2026 |
| CAGNONI PABLO J | officer: President, R&D | Sell | −18,667 | $1.8M | Mar 17, 2026 |
| CAGNONI PABLO J | officer: President, R&D | Sell | −18,668 | $1.9M | Feb 19, 2026 |
| Issa Mohamed Khairie | officer: EVP, Head of US Oncology | Sell | −10,856 | $1.2M | Jan 07, 2026 |
| Stein Steven H | officer: EVP & Chief Medical Officer | Sell | −15,634 | $1.6M | Jan 05, 2026 |
| Tray Thomas | officer: Principal Accounting Officer | Sell | −2,774 | $277.4K | Dec 19, 2025 |
| Tray Thomas | officer: Principal Accounting Officer | Sell | −600 | $59.0K | Dec 18, 2025 |
| Morrissey Michael James | officer: EVP, Head of Tech. Operations | Sell | −4,323 | $420.5K | Dec 17, 2025 |
| Morrissey Michael James | officer: EVP, Head of Tech. Operations | Sell | −53,175 | $5.2M | Dec 16, 2025 |
| Morrissey Michael James | officer: EVP, Head of Tech. Operations | Sell | −833 | $81.2K | Dec 16, 2025 |
| Mayes Patrick A | officer: EVP & Chief Scientific Officer | Sell | −255 | $24.2K | Dec 11, 2025 |
| Mayes Patrick A | officer: EVP & Chief Scientific Officer | Sell | −5,553 | $530.8K | Dec 10, 2025 |
Transaction mix · 180d
100%
Sells12 · $14.8M
Buys0 · $0
Top sellers · 180d
Morrissey Michael James · officer: EVP, Head of Tech. Operations−$5.7M
CAGNONI PABLO J · officer: President, Global Head of R&D−$5.4M
Stein Steven H · officer: EVP & Chief Medical Officer−$1.6M
Transactions
12
0 buys · 12 sells
Bought
$0
Open market
Sold
$14.78M
Open market
Net flow
−$14.78M
Buys − sells
Transactions
| Insider | Role | Action | Shares | Price | Value | Trade date | Filing |
|---|---|---|---|---|---|---|---|
| CAGNONI PABLO J | officer: President, Global Head of R&D | Sell | 18,667 | $96.50 | $1.8M | Apr 17, 2026 | Apr 21, 2026 |
| CAGNONI PABLO J | officer: President, R&D | Sell | 18,667 | $94.24 | $1.76M | Mar 17, 2026 | Mar 19, 2026 |
| CAGNONI PABLO J | officer: President, R&D | Sell | 18,668 | $100.91 | $1.88M | Feb 19, 2026 | Feb 23, 2026 |
| Issa Mohamed Khairie | officer: EVP, Head of US Oncology | Sell | 10,856 | $109.07 | $1.18M | Jan 07, 2026 | Jan 08, 2026 |
| Stein Steven H | officer: EVP & Chief Medical Officer | Sell | 15,634 | $101.70 | $1.59M | Jan 05, 2026 | Jan 07, 2026 |
| Tray Thomas | officer: Principal Accounting Officer | Sell | 2,774 | $100.00 | $277.4K | Dec 19, 2025 | Dec 22, 2025 |
| Tray Thomas | officer: Principal Accounting Officer | Sell | 600 | $98.25 | $58.95K | Dec 18, 2025 | Dec 22, 2025 |
| Morrissey Michael James | officer: EVP, Head of Tech. Operations | Sell | 4,323 | $97.26 | $420.45K | Dec 17, 2025 | Dec 18, 2025 |
| Morrissey Michael James | officer: EVP, Head of Tech. Operations | Sell | 53,175 | $97.29 | $5.17M | Dec 16, 2025 | Dec 18, 2025 |
| Morrissey Michael James | officer: EVP, Head of Tech. Operations | Sell | 833 | $97.42 | $81.15K | Dec 16, 2025 | Dec 18, 2025 |
| Mayes Patrick A | officer: EVP & Chief Scientific Officer | Sell | 255 | $94.94 | $24.21K | Dec 11, 2025 | Dec 12, 2025 |
| Mayes Patrick A | officer: EVP & Chief Scientific Officer | Sell | 5,553 | $95.58 | $530.76K | Dec 10, 2025 | Dec 12, 2025 |
By insider
- Morrissey Michael James−$5.68Mofficer: EVP, Head of Tech. Operations0B · 3S
- CAGNONI PABLO J−$5.44Mofficer: President, Global Head of R&D0B · 3S
- Stein Steven H−$1.59Mofficer: EVP & Chief Medical Officer0B · 1S
- Issa Mohamed Khairie−$1.18Mofficer: EVP, Head of US Oncology0B · 1S
- Mayes Patrick A−$554.97Kofficer: EVP & Chief Scientific Officer0B · 2S
- Tray Thomas−$336.35Kofficer: Principal Accounting Officer0B · 2S
Beneficial ownership filings
Schedule 13D / 13G — investors holding more than 5% of INCY-US.
DB · acquisition_ownership6
| Filed | Reporting person | Form | Type | Aggregate owned | % Class | Sole voting | Shared voting | Citizenship | |
|---|---|---|---|---|---|---|---|---|---|
| Nov 08, 2024 | (1) BlackRock, Inc. | — | HC | — | +8.90% | 15.86M | 0 | Delaware | SEC → |
| Oct 21, 2024 | (1) BlackRock, Inc. | — | HC | — | +8.90% | 0 | 0 | Delaware | SEC → |
| Oct 17, 2024 | STATE STREET CORPORATION | — | HC | — | +5.50% | 0 | 7.42M | MA | SEC → |
| Mar 25, 2024 | Incyte Corporation | — | CO | — | +6.90% | 4M | 0 | Delaware | SEC → |
| Feb 14, 2022 | PAGE 2 OF 4 PAGES | — | IA | — | +7.50% | 15.97M | 0 | — | SEC → |
| Oct 12, 2021 | 52-0556948 | — | IA | — | +8.50% | 6.93M | 0 | Maryland | SEC → |
Top 10 holders · 8 quarters
13F position evolutionNo 13F history in
institutional_holders for INCY-US.